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Hashimoto’s patients have in some cases both stimulating 
and blocking antibodies [2, 3]. It stands to reason that if the 
patient is hypothyroid, then blocking antibody avidity and/
or titer would dominate irrespective of the presence of stim-
ulating antibodies. There is a growing list of publications 
that show the prevalence of TSHR stimulating autoantibod-
ies in HT patients using bioassays. Wall et al. [4] found that 
22 % (4/17) HT patients without thyroid-associated orbit-
opathy (TAO) were TSI positive using Thyretain™ TSI 
Reporter BioAssay. Another clinical study using a different 
bioassay had similar conclusion and showed 7 % of the HT 
patients have stimulating autoantibodies [5]. A recent pub-
lication by the authors of the subject manuscript showed 
that 5.5 % of HT patients and 68.2 % of HT patients with 
TAO were TSI positive when tested with the Thyretain bio-
assay [6]. Astonishingly, the authors did not test the HT 
samples with the stimulating bioassay for this study and 
only tested them with the blocking bioassay. Therefore, we 
do not know the stimulating autoantibody status of the HT 
patients. Furthermore, the HT population selected appears 
to not be random as all tested positive with blocking bio-
assay. The prevalence of TSHR blocking autoantibodies 
in HT patients is reportedly 9 % [7]. The IMMULITE TSI 
assay has a published specificity of 96.4 % when 111 ran-
domly selected HT patients were evaluated [1]. Independ-
ent clinical studies have confirmed the high performance 
of IMMULITE TSI assay showing 100 % sensitivity and 
98 % specificity with GD and HT patients [8, 9]. The test-
ing of the HT patients with the Thyretain bioassay may fail 
to detect all the stimulating antibodies due to its lower sen-
sitivity (92 % according to Thyretain assay package insert) 
compared to the IMMULITE TSI assay with 98.6 % sensi-
tivity. Stimulating antibody tests that do not rely on bioas-
say will detect stimulating antibodies even in the presence 
of blocking antibodies allowing the physician to monitor 
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We wish to share our concern with the scientific design, 
validity and results of the work by T. Diana, C. Wuster, M. 
Kanitz and G. J. Kahaly published in your journal (Highly 
variable sensitivity of five binding and two bioassays for 
TSH-receptor antibodies, J. Endocrinol. Invest. Published 
online 19 May 2016, doi:10.1007/s40618-016-0478-9). 
In this publication, the authors conclude that sensitiv-
ity is highly variable between binding and bioassays for 
TSH-receptor antibodies (TSHR-Abs). In fact, they incor-
rectly identified one of the commercial assays, the Siemens 
IMMULITE® 2000 TSI assay, as a TSHR-binding inhibi-
tory immunoglobulins (TBII) assay (in multiple instances 
throughout the manuscript). This is incorrect as the IMMU-
LITE TSI assay has a patented, novel “bridge” format for 
the direct detection of thyroid stimulating autoantibodies 
to TSHR and does not rely on binding inhibition of TSH 
or any other ligand used in TBII assays. It also has a pub-
lished independently derived 98.6 % sensitivity and 98.5 % 
specificity when tested with patients suffering from a vari-
ety of thyroid and autoimmune diseases including Hashi-
moto’s thyroiditis (HT) [1].
In their study, the authors tested various samples from 
patients with Graves’ disease (GD) and observed a 95 % 
sensitivity for the IMMULITE TSI assay which is close 
but lower than the published 98.6 % (95 % CI 96.8–99.5) 
sensitivity [1]. The authors tested 20 hypothyroid Hashimo-
to’s patients with a blocking bioassay and several binding 
assays and obtained positive results. This is expected since 
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the natural history of the thyroiditis and anticipate the 
potential for latent development of Graves’ disease.
In addition to the misrepresentation of the IMMULITE 
TSI assay, we discovered several errors in the data analy-
sis and the results. The authors report in Table 2 that all 20 
HT patients tested positive with Roche’s assay. However, 
Table 4 shows that the results had a (min–max) range of 
0.3–40 IU/L. Given the assay’s cut-off of 1.75 IU/L, it is 
clear that (at least) one HT sample (with reported dose of 
0.3 IU/L) was negative in Roche’s assay, contrary to the 
data presented in Table 2. Secondly, Table 2 shows zero HT 
patients for both TSAb+ and TSAb− categories which is a 
contradiction in itself. If zero patients were TSAb + , then 
all 20 HT patients must have been TSAb- or vice versa. The 
same contradiction appears for the healthy controls and GD 
patients, zero healthy patients are TSAb+ and zero patients 
are TSAb−. Thirdly, the data presented in Table 2 mislead 
the reader into thinking TSAb tests were run and none of 
the HT patients were positive when in fact according to the 
text in Results section, HT patients were only tested with 
the TBAb (blocking) bioassay. Therefore, this study is 
incomplete and inconclusive as the authors neglected to test 
HT patients with the TSAb assay despite various publica-
tions, including the authors own previous work, showing 
the prevalence of TSHR stimulating autoantibodies in HT 
patients [6].
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